arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Intellia Therapeutics, Inc.

NTLA
$12.35 ▼ -0.34 (-2.68%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
48 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Intellia Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.6B
Dividend Yield —
Revenue Growth -46.2% ↘
Op. Margin None
ROIC -12.2% ↗
FCF / Share $-0.64 ↗
Trailing P/E —
Price / Book 2.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

48-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.66M
↓ -46.2% —
Net Income Profit after all expenses
$-96.23M
↑ +15.8% —
Operating Margin Operating profit as % of sales
-428.9%
↓ -8.8% —
FCF / Share Free cash flow per share
$-0.64
↑ +35.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
14
Cash Quality ↑
63

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 48 quarters